Comparative Pharmacology
Head-to-head clinical analysis: ESGIC PLUS versus NEMBUTAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESGIC PLUS versus NEMBUTAL.
ESGIC-PLUS vs NEMBUTAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Esgic-Plus is a combination of acetaminophen (analgesic/antipyretic via COX inhibition and central action), butalbital (barbiturate that enhances GABA-A receptor activity), and caffeine (adenosine receptor antagonist and CNS stimulant). The mechanism for treating tension headache is attributed to the synergistic effects of these components.
Barbiturate that enhances GABA-A receptor activity, increasing chloride ion conductance and neuronal hyperpolarization. At high doses, has direct inhibitory effects on excitatory AMPA and kainate receptors.
1-2 capsules (acetaminophen 500 mg, butalbital 50 mg, caffeine 40 mg per capsule) orally every 4 hours as needed, not exceeding 6 capsules per day.
Induction of anesthesia: 50-120 mg IV as a single dose. Maintenance of anesthesia: additional doses of 20-40 mg IV as needed. For sedation (preoperative): 100-200 mg IM or 1-5 mg/kg IV 1-1.5 hours before procedure. For status epilepticus: loading dose of 5-15 mg/kg IV slow push, then 1-5 mg/kg/h IV infusion.
None Documented
None Documented
Butalbital: 35-70 hours in adults; prolonged in hepatic/renal impairment. Acetaminophen: 2-3 hours in adults; extended in overdose (potential hepatotoxicity). Caffeine: 3-6 hours in adults; increased in pregnancy or liver disease.
Terminal elimination half-life is 40-120 hours (mean ~80 hours). The prolonged half-life contributes to accumulation with repeated dosing and residual sedation.
Butalbital: 60-90% renal as unchanged drug and metabolites, 10-40% fecal via biliary elimination. Acetaminophen: ~85% renal as glucuronide (45-55%), sulfate (25-35%), and cysteine conjugates (4-15%); 2-4% unchanged. Caffeine: ~85-90% renal as metabolites (1-methylxanthine, 1-methyluric acid, 1,7-dimethylxanthine); 1-3% unchanged.
Renal elimination of unchanged drug accounts for approximately 30-35% of a dose; the remainder is hepatically metabolized. Less than 5% is excreted unchanged in feces.
Category C
Category C
Barbiturate/Narcotic Combination
Barbiturate